u/tomas_lundgren

What was the exposure in that experiment relative to therapeutic?

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

What did the storefront say the lead time was?

That is a complaint rather than a proposal. Bring wording and it can actually be discussed.

Reported something here with dates and screenshots and was asked for the document trail. Fair challenge, and it made the report worth reading.

Careful. What you are describing is a delayed shipment, and this board should not turn that into an accusation without more.

gastric emptying slows, it does not stop

results without method are gossip with decimals

I would not post that as a finding. It is a single result and the template asks you to say so.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

group buys concentrate risk in one person and nobody plans for that

split a vial across two services once and you will never argue about ground truth again

Vendor source pages carry an outbound link to the supplier’s own storefront, marked nofollow and sponsored, disclosed on the page and again on the fun

Disagreeing with this bit: making individual cases public by default is worse for the person being moderated.

vendor, compound, batch, service, result — that is the template

nobody here is paid, including the moderators

nothing containing this is approved anywhere yet

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

Resistance training, and at what frequency?

Nearly paid a cloned storefront. Caught it because one character in the domain was wrong and I paste rather than type.

Feed position is a function of early votes and time. That structurally favours agreeable early answers over correct late ones, which is why sorting by controversial occasionally is worth the effort.

gastric emptying slows, it does not stop

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.

That is a report count, not a test count, and it changes how thin the evidence base actually is.

Same. Volume over novelty. Changing programme every six weeks cost me a year.

What is the concrete wording you would replace it with?

glucagon agonism sounds paradoxical until you read the energy expenditure work

Yes — time in range tells you about variability, which the average deliberately hides.

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

Yes. The central component is the one that explains the reports on this site better than gastric emptying does.

Same. Volume over novelty. Changing programme every six weeks cost me a year.

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

Agreed. A1c is an integrated average over roughly three months and treating it as a current reading causes a lot of unnecessary alarm.

What was the exposure in that experiment relative to therapeutic?

That reading assumes area percent and net peptide content are the same number. They are not, and the report says which it is.

Which rule specifically, and which part of it?

This. Hypoglycaemia risk in this class is driven mostly by the other agents in the regimen.

A1c, CGM, or fingersticks — which are we discussing?

time in range is the more informative number and it is newer

Assumed the weight endpoints from the obesity trials applied to my situation. They are different programmes.